Annual Review 2022
Sponsored by
Media Partner
Premier R&D service provider for the life science industry
Global CRO partner to bring your therapies to life CGT Webinar Series
Join our upcoming expert-led webinars that focus on R&D industry trends and opportunities
DMPK Webinar Series Chemistry Lecture Series
Chemistry, Manufacturing & Control
Biologics & CGT
Process Chemistry & Analytical Development Material Science GMP API Manufacturing Formulation Development Drug Product Manufacturing Commercial-scale Manufacturing
Discovery Biologics Biologics CDMO CGT Lab Services CGT CDMO – Viral Vectors and Plasmid DNA Biologics & Viral Analytics and Characterisation Cramlington
Clinical Development
Laboratory Services
Radiosynthesis C (including 3 GMP) & H 14 Non-clinical ADME ( C/ 3H) Pharmacology Models ( 14C/ 3H) Clinical Bioanalysis (GCP) Clinical Pharmacology Environmental Assessments
Synthetic & Medicinal Chemistry Analytical Chemistry Computational Chemistry & CADD DMPK/ADME Biology & Pharmacology Medical Device Evaluation Safety Assessment
14
Liverpool
Rushden Cardiff
Hoddesdon
UK Facilities
Cardiff
|
Cramlington
|
Hoddesdon
|
Liverpool
|
Rushden
pharmaron.com bd@pharmaron.com
Contents Welcome ......................................................................................................... 4-6 Innovation Support...................................................................................... 7-8 Learning & Development......................................................................... 9-11 Events .......................................................................................................... 12-17 Meet the Team ................................................................................................ 19 Our Corporate Supporters ..........................................................................20 Our Corporate Patron .................................................................................. 21 One Nucleus Partners .................................................................................. 22 Partner Programme ...................................................................................... 23 Member Benefits ..................................................................................... 25-26 Member Savings ...................................................................................... 27-29 Facilities Management ................................................................................ 30 East of England Deal Making Activity.............................................. 32 -35 Providing Space for the Pioneers of Life Sciences.............................. 37 Increasing Sophistication in the Pharma/Biotech Partnership Model.................................................................................................................. 39 It Takes a Network ................................................................................. 41 - 45
Member Listings: A-Z Listing ................................................................................................. 47-54 Find Out More ................................................................................................ 55
www.onenucleus.com | 3
A Warm Welcome from Tony Jones This yearly publication provides the opportunity for us to reflect on a year of One Nucleus activities, to highlight some of the successes and gained insights among our members and the wider Life Sciences sector. Further, it is also a chance to share with our network some thoughts and plans we have for the year ahead with regards to our focus and how we aim to offer the best support to the membership. I am delighted this year that we have included more details of the activities delivered in 2021 since these are not a simple reflection of what the One Nucleus team has been doing but also illustrates well what our network has engaged in as it continues to adapt to a world coming out of the pandemic. Learning Lessons from Challenges Business practices changed for all when it came to deal making, workplace operations and everyone’s daily life as we encountered the pandemic. The uncertainty remains in some respects of course and it seems inevitable that after such a disruption, things will not just return to the pre-Covid business-as-usual operations. Lessons are always learned from challenges, we must hope to retain some of the efficiencies that were introduced. It was exciting to hear at numerous One Nucleus events and other meetings how the sector’s thought leaders have adopted new ways of working with the intention of accelerating the translation of great innovation into a more integrated patient benefit. Highlights in this Review Within this review you will get the opportunity to read some contributed editorial articles from PharmaVentures, BioMed Realty and Mills & Reeve along with learning about the highlights from our own One Nucleus work. This will include a recap of our conferences (Building Life Science Adventures, ON Helix and Genesis) as well as click throughs if you’d like to catch a recording of sessions you missed or would like to see again. This latter option a benefit of it having been necessary to turn to virtual events. This recording option for on-demand catch-up is an offer we have retained whilst returning to in-person events on a regular basis. The review of One Nucleus activities will continue as you read, to provide updates on our Virtual Innovation Centre, Training Courses that sixty companies have utilised, the launch of our ‘Employer of Choice’ and Mentoring scheme after topics aired at BLSA 2021, the forty-nine nonconference events, the Member Savings performance and how we have advised on a record level of R&D Space design and fit-out to name but some. Not just a listing of the One Nucleus membership offer, but the data that illustrates how we deliver.
4 | One Nucleus Annual Review & Directory 2022/2023
Sector Resilience and Activity 2021 was another record-breaking year when it came to investment attracted by the Life Sciences industry. By way of example, $7.3Bn was invested globally in just Jun-Aug 2021, led by the US at $4.37Bn. The UK continued to lead in Europe at $429M in that period whilst over the year as a whole the UK Life Sciences sector raised £4.5Bn, a staggering £1.7Bn more than in 2020 (cf Clarivate & BIA). One Nucleus members including Artios Pharma, Microbiotica, Healx and Nuclera Nucleics are just some of those who raised significant rounds. It’s not just about venturebacked companies either. Our Corporate Patron, AstraZeneca is predicted to generate the biggest new sales in 2022 estimated at $7.0Bn (Evaluate Vantage). The excellence in translational research within our membership is magnetic to others wanting to locate or work with the region with not just the primary bio-venture investment that powers the growth here. The ability to attract scientific talent, the growing pool of experienced innovative business leaders, strong networks and global connectivity means the entire ecosystem attracts a meaningful portion of revenue flows from within the industry. The impressive growth of R&D partners such as Domainex, Abzena and Phoremost, who are leveraging their proprietary platforms to attract deals whilst developing their own asset pipelines, is illustrated by them all expanding into larger facilities recently as their client base has grown. How We Support the Network Taking the feedback from our members on board as we continue to evolve the One Nucleus value proposition, we seek the best ways to: •
Support innovation and those organisations and leaders driving translation of their innovation towards new healthcare interventions to improve patient outcomes.
•
Enable the connectivity of all stakeholders, each bringing their unique combination of expertise, resource and dynamism to the sector and seeking to collaborate.
•
Promote the career opportunities the Life Science industry offers, whether those careers are at the bench, in business or within the wider ecosystem.
•
Inform our members of the latest developments and trends across all topics including reference to operational roles such as HR, Marketing and Purchasing through our thematic group sessions.
•
Enable access to the optimal meeting opportunities, whether in-person or online and whether these are forums delivered directly by One Nucleus, in collaboration with others or at discounted rates to commercial events such as BioEurope, Biotech Integrates and BioTrinity.
•
Promote good practice in the area of being a good employer and corporate citizen. Adopting better practices ourselves where possible and importantly showcasing the good practice to our network and encouraging wider adoption.
www.onenucleus.com | 5
Focus is Key By way of completing this welcome section, I include here the framework of focus areas the One Nucleus team has developed to help guide our various activities and performance for our stakeholders.
INNOVATION SUPPORT • • • • • • • •
Virtual Innovation Centre (VIC) Knowledge Exchange Member Savings Learning & Development Recruitment & Retention Facilities Support Profile & Promotion Government Support Opportunities
STAKEHOLDER ENGAGEMENT • • • • •
EVENTS • • • • • •
Conference Portfolio - (ON Helix, Genesis, Building Life Science Adventures) Innovation Seminars/Round Tables BioWednesdays Peer-to-Peer Networking Events Collaborative Events
Sponsors & Members The Life Science Sector Policy Influencers Collaborators Patients
BUSINESS PRACTICE • • • • •
Improving Business Resilience Being an Employer-of-Choice Sustainability in Action Supporting Diversity Community Engagement
Looking Ahead I, or indeed any member of the One Nucleus team detailed in what follows, stand ready and willing to discuss any of the work we do and opportunities engaging with One Nucleus can present. I hope you enjoy the various articles, updates and window on our forward-looking plans contained in this 2022 Annual Review. I very much look forward to meeting again soon and supporting you on your journey to success. Best wishes, Tony Jones, CEO
6 | One Nucleus Annual Review & Directory 2022/2023
Innovation Support If starting-up a life science company is hard, growing that company comes with the exponential challenges of becoming increasingly operational as well as active dealmakers. It is from this observation and based on the One Nucleus strengths and connectivity that the Virtual Innovation Centre concept emerged in 2021 as a supporting tool for Life Science companies on their growing journey. Analyses – like this very interesting article from McKinsey – often point to the translation of science and innovation into commercialisation as the weak point in European Life Sciences. Many causes keep being identified, such as the smaller size of initial funding rounds, lack of managerial expertise, or company culture, but none of those factors are terminal and this is where the power of a network can be leveraged. The One Nucleus Virtual Innovation Centre is working on four key areas to support growing Life Science companies. Detailed here is what is being delivered, and how, in terms of support: Preparation and access to capital Raising money is an on-going task for Life Science entrepreneurs but the role evolves as the company grows, along with the type of investor and their expectations and demographic. The VIC delivered sessions supported by its partners Oyster Venture Partners and Taylor Wessing on the topics of Transactions for Growth and Best Practices to De-risk your Fundraising covering how to best prepare for different deals and investment types. These sessions are complemented by the One Nucleus investors’ network which is very active in the ecosystem. Developing deal making activities Companies’ development journeys will converge with deal making, whether in the form of research collaboration or contract research and outsourcing with suppliers or clients. This element contains a need to build commercial connection. The VIC has helped companies like Leaf Expression System and Eagle Genomics by involving them in One Nucleus’ flagship conferences ON Helix and Genesis. It also requires technical knowledge, that our partners Penningtons Manches Cooper, Fish & Richardson and pharma partners such as Lilly provide, with sessions such as Anatomy of a Research Collaboration Agreement Enhancing R&D capacities and outsourcing Fundraising and deals only happen when companies generate enough innovation. This obvious statement means that the capacity to grow R&D capacity and plan later stage development is essential to companies’ success. The VIC is fortunate to include a breadth of development partners including Catalent, Charles River, Lonza, Thermo Fisher and tranScrip who shared their expertise in sessions such as Growing Lab Capacity including Outsourcing, Purchasing and Digitally Native lab, and the session Growing with Underlying Principles of Drug Development.
www.onenucleus.com | 7
Innovation Support Strengthening business operations. This element is rarely at the forefront of companies’ priorities, however it is as essential as the R&D operation in growing a business successfully. This is why supporting this part is crucial, so entrepreneurs can concentrate on delivering good science and the strategic developments. Our executive recruitment experts George James and law firm Penningtons Manches Cooper offered advice and shared their expertise during sessions on the topics of Identifying and Filling Gaps in the C-suite and Board and Growing with Confidence in Employees We had good engagement with the following companies over the year who benefitted from the sessions, contacts and opportunities offered within the One Nucleus conferences. Biorelate, Broken String Biosciences, Carocell Bio, Colorifix, Curileum Discovery, Drishti Discovery, Eagle Genomics, ET-traps, Kantify, Leaf Expression Systems, Mestag Therapeutics, Monument Therapeutics, MultiplAI Health, Nuclera Nucleics, Pharmenable, Semarion, Talisman Therapeutics, Valirx. We’re looking forward to continuing to support them and others who would like to join us on their journey. For more information, please contact Aline Charpentier, Head of Innovation Support at One Nucleus.
• • • • • •
12 month tailored seminar programme. 1-2-1 meetings with leading experts. Profile at One Nucleus and external conferences. Directed 1-2-1 introductions. International connectivity. Gold membership benefits.
8 | One Nucleus Annual Review & Directory 2022/2023
Learning and Development Focus and news flow is often on highlighting world leading technology breakthroughs and impressive investment rounds and deals in the Life Sciences sector as life-changing products are invented and translated to improved patient care. It is vital not to forget the third pillar that supports the enviable track record. Inventions, collaborations, deals and therefore impact requires people. One Nucleus supports members, individuals and the wider sector through a suite of interventions targeted to meet the aspirations of our members which can be summarised as follows: Attract the best talent and skills. Engender loyalty. Harness the strengths of diversity. Encourage innovation at all levels. Be a good corporate citizen delivering value for all stakeholders.
Motivate their employees. Operate an open and safe environment. Enable personal development of their staff. Deliver fair reward for performance. Offer flexibility to meet business and employee needs in an equitable manner.
Learning & Development: Business leaders frequently confirm that their company’s employees are its most valuable assets. A mantra that has never been more relevant than now when competition for the best people has never been more intense. Retention and development of staff is as key to successful growth as effective recruitment. We have developed a range of Learning and Development support opportunities including: •
A broad Training Course portfolio, delivered face-to-face or online to meet member companies’ needs.
•
Training Courses can be delivered in-house for a single company or open courses as required.
•
Members receive up to 30% discount on Training Courses when booking.
•
Free on-demand content from our events and conferences to fill knowledge gaps within teams.
Recruitment & Retention: •
Website listing of job vacancies.
•
Focussed ‘Employer of Choice’ sessions to discuss best practice.
•
Thematic forums in Skills and HR.
•
Annual Building Life Science Adventures conference.
People Pathways Newsletter: •
Monthly e-publication disseminated to our network.
•
Learning & Development insight articles.
•
Recent appointments at member companies.
•
Current vacancies.
•
Up-coming Training Courses.
For more information, please email our One Nucleus Learning and Development team
www.onenucleus.com | 9
Learning and Development in Review During the past 12 months we have been encouraged to see a continued uptake in training courses with both open and in-house delivery amongst member companies. Through feedback we know that whilst the development of staff is important, retention of those staff is certainly key in an increasingly competitive recruitment market.
In 2021, 60 companies booked onto an even spread of compliance and essential skills courses, delivered both online and in-person, and we saw an increase in the number of member and nonmember in-house courses delivered. Employer of Choice The growth in competition to secure and retain the best employees, the changing career and working flexibility aspirations of those employees and the desire of our leaders to align with societal changes with regards to Equality, Sustainability and Governance (ESG), in 2021 saw the launch of our Employer of Choice webinar sessions. These sessions covered topics as wide ranging as women’s health and safety at work; reducing carbon footprint; LGBTQ+ inclusion; working with neurodiversity and more. The common thread being to engage employers in how to build their best Employee Value Proposition. Watch the Employer of Choice Sessions here We welcomed 96 attendees joining sessions on: •
Wellbeing – Helping Employees Stay in Tune
•
Women’s Safety in the Workplace
•
Women’s Health and Wellbeing in the Workplace
•
Reducing Carbon Footprint
•
Creating a Diverse and Inclusive Workplace
10 | One Nucleus Annual Review & Directory 2022/2023
Building Life Science Adventures Careers Conference 2022 This year saw 194 attendees and 50 speakers participate. The topics covered:
• How do You Build People Skills? • How
Much Should You Value Experience Over Qualifications? • Reinventing Recruitment Post-Covid and Diversity and Inclusion Progressing from Intention to Practice • How Will AI Change Life Science Careers? • Is Being an Entrepreneur a Career? • Do Role Models Make Great Mentors? • Fishing in a Global Pond • BioWednesday Webinar: What is the Best Use of Carbon in the Life Science Sector? Watch the sessions here Looking forward to next year’s BLSA - SAVE THE DATE - 28–29 March 2023!
NEW! One Nucleus Mentoring Initiative The One Nucleus Mentoring Initiative was created in summer 2021, with several of the panels at Building Life Science Adventures 2021 having highlighted its importance. Being surrounded by and learning from great people was deemed important in all stages of a career. We are here to help find a mentor - it’s our chance to play our full role in connecting the expertise and know-how of our network to those that need it and thereby collectively enhancing the success of the cluster. Contact training@onenucleus.com with details about what you currently do, the type of mentor you seek and the area of expertise on which you seek their guidance. Free of charge, we’ll advertise your mentor vacancy on our LinkedIn, Twitter, website and monthly People Pathways newsletter. The image above is an example of what the advert could look like. We will keep you updated and connect you to those who get in touch. Since launching, mentors have supported and guided mentees through key business decisions, new careers, internship/placement advice and more. We collaborated with the Society for Laboratory Automation and Screening (SLAS) to enhance the mentee experience. Those that signed up for the SLAS Mentor Match programme received access to a complimentary 6-month membership with SLAS. Recruitment & Retention - Our job vacancies page has been extended to non-members for a fee, and we set up a Linkedin Group for HR opportunities. We continued to offer our range of themed webinars on Skills and HR. People Pathways Newsletter People Pathways is a monthly e-publication disseminated to our network, covering Learning & Development insight articles, recent appointments at member companies, current vacancies and upcoming Training Courses. For more information, please email our One Nucleus Learning and Development team
www.onenucleus.com | 11
Events Events are an essential part of the One Nucleus offer. In addition to our flagship conferences, we deliver a range of events where members and non-members showcase their expertise and enable knowledge exchange, debate and networking between members and non-members. The main categories of our events are illustrated below alongside the numbers delivered for each throughout the past year:
Innovation Seminars – Includes full day/half day/breakfast sessions on technical topics including solutions to challenges in R&D as well as law, IP and finance topics. This series includes sessions that are part of the One Nucleus Virtual Innovation Centre programme to support early-stage companies as they become increasingly operational. Thematic Groups – Focused sessions covering updates and best practice discussions on HR, Marketing and People related topics. BioWednesdays – Monthly member benefit events that bring our network together over key topics and networking. Networking Mixers – A chance to network and connect with the One Nucleus Life Science community in a less formal environment such as social venues and over dinner. Whether you are looking to attract your next collaborator, client or investor, our events are an excellent opportunity to help you make new connections and to fill knowledge gaps to help facilitate your growth. They are open to members and non-members with members gaining free and discounted access to some, while others are open and free to all. As the chart below illustrates, we have a good representation of both members and non-members at our events, reflecting the wider audience that they attract.
12 | One Nucleus Annual Review & Directory 2022/2023
We look to our members first for speaking opportunities and over the past year have recruited >100 speakers for our events. We also have sponsorship opportunities available for those looking to raise their profile with this key network. In the past year, One Nucleus has been proud to work with sponsors including: EVENT SPONSORS
Our events cover a wide breadth of topics that are relevant to the local Life Science community, highlighting the region’s strengths and also reflecting the evolution of the sector including technology trends. Some will also leave delegates with practical tips to take away! Below are some stand out topics from the past year to highlight what our network has been talking about. BioWednesday Webinar: Enabling AI in Drug Discovery - A session in collaboration with Stevenage BioScience Catalyst that discussed how AI is impacting drug discovery and beyond, and how companies can mature innovation in this space in terms of which business model to use, accessing and raising investment and recruiting skilled staff. The recording of this session can be accessed here. BioWednesday Webinar: Opportunities for UK Life Sciences - A US Perspective - A session in collaboration with Fish & Richardson that discussed the strengths and weaknesses of the UK’s position in global biotech and what this means for UK companies seeking investment, deals and alliances in the US. The recording of this session can be accessed here. Advanced Biobanking: Learn from IBX How to Harness the Potential of Biobanks - A member webinar sponsored by Infinity BiologiX that shone a light on the importance of biobanking and sharing high quality data to ensure the future success of genomic and regenerative medicine. The recording of this session can be accessed here. Networking Mixer at Queen Mary Enterprise Zone - An opportunity for members and nonmembers to connect. This event featured a speaker from the Digital Environment Research Institute (DERI) and Deep Science Ventures to help set the scene for the networking that followed. Life Science Marketing Group: The Transition from Virtual to Hybrid and Live Events for the Life Sciences Sector - In collaboration with Giggabox and a hot topic for many in the industry following the pandemic which saw the world of virtual and live events merge. The recording of this session can be accessed here.
www.onenucleus.com | 13
Focus on One Nucleus’ Core Events
This one-day conference will address the main bio innovation trends, from the developments in life science and technology research to their translation into new diagnostics, prevention tools or treatments. Don’t miss this opportunity to reconnect with the One Nucleus network and keep up to date with the latest trends in Bio Innovation for Health. ON Helix 2022 offers: • a high content mix of plenary talks and panels from key opinion leaders • networking with 250+ delegates • 1-to-1 virtual meetings with in-person and digital only delegates • ON Helix Fringe events from 4 July including digital Innovation Workshops • an ‘Innovation Engine Room’ showcasing the most innovative early-stage life science companies and innovation supporters from the network.
Genesis assembles senior executives and decision-makers from across the Life Science, Healthcare and Technology field to present, discuss and demonstrate their collective insight and thought leadership for the sector, themselves and their stakeholders. Genesis offers: • a high content mix of plenary talks and panels from key opinion leaders • Innovation Workshops for further technical and business insights • Face to face networking and digital 1-2-1 meetings with delegates from across the international Life Science and Healthcare industry • popular Fringe Events.
Creating careers not just jobs is a two-way process between those seeking to build their adventures in science and those seeking to employ them with academia a critical enabler. This two-day free to attend digital careers conference is a chance to fill knowledge gaps, debate best practice and connect to enable success. Not your standard job fair, this is an event bringing panels of students, early career seekers, employers and universities together to engage in lively discussions over the course of two days.
14 | One Nucleus Annual Review & Directory 2022/2023
ON Helix and Genesis in 2021 – Reconnecting the ecosystem After a full year of digital conferences, 2021 highlighted a need for reconnection, albeit remaining digital for ON Helix in July with 400+ delegates but excitingly in-person for Genesis in December where more than 200 delegates enjoyed connecting with peers. Although ON Helix and Genesis have a slightly different foci and therefore audiences, they share the same purpose; conferences designed with and for the One Nucleus network. Beyond the exciting connection opportunities, it means that discussion topics are those our network want to engage with and can contribute to. Here is a look at the key highlights:
ON Helix 2021 – New Medicines in a Brave New World Following 2020 and the way the life science community combined resources, ingenuity and hard work to deliver prophylactic and therapeutic tools against the pandemic, ON Helix addressed the lessons learnt on how translation of science into developing new therapeutics and healthcare technologies can be improved and in addition, how to collectively build this ‘Brave New World’. The one and a half days of live sessions covered some of the key technology trends such as mRNA technologies, innovations in drug discovery and the diagnostics revolution as well as the wider environment making them possible, including talents, research funding and ecosystems. ON Helix 2021 also highlighted the drive to greater sustainability with a keynote introduction from Penny James, COO R&D Biopharmaceuticals at AstraZeneca, articulating the efforts the industry was making in this domain and AstraZeneca in particular. For the first time the agenda included non-medical life science companies to discuss their own contribution to health by developing more sustainable processes (Colorifix, Leaf Expression Systems) or alternatives to animal products (Higher Steaks).
Keynote Speaker: Penny James, AstraZeneca
As this event was still digital, it was also packed with really exciting on-demand content including the Biotech Rising Star pitches presenting the next generation of biotechs; a series of discussions on ecosystems as enablers for talent, digitalisation or entrepreneurship; and fireside chats with top level industry representatives including Francesco de Rubertis, Centessa Founder and Claire Skentelbery, Director General, EuropaBio and many more! Because we like to share these insights with our network, the full ON Helix 2021 playlist is available on the One Nucleus YouTube channel.
Delegates engaged with ON Helix via an app
www.onenucleus.com | 15
Genesis 2021 – Celebrating our 21st anniversary in style Genesis is our annual end of year conference bringing together the One Nucleus network of key industry leaders to reflect on the past year’s most significant trends in innovation as well as macro trends such as deals, investment and corporate considerations. As 2021 was another exciting year for the life science sector, there were many insightful and thought-provoking discussions covering: • Money and the enormous influx of cash we have seen translated in an impressive level of deal activity. It brought a lot of optimism about how resources and interest gained by our industry could have significant impact on reducing the time it takes to bring innovation to patients. • Drugs and the lessons learnt to accelerate the development of new medicines brought on by Covid vaccine success stories. •
Patients, that we were reminded we all are, and the importance of patient centricity at the earliest stages.
•
Technology, especially the adoption of genomics to improve healthcare delivery.
•
Innovation, and how to learn from other sectors like automotive, engineering, retail and performing arts.
Sessions are available on the One Nucleus YouTube channel.
16 | One Nucleus Annual Review & Directory 2022/2023
The Events’ Innovation Workshops – Sharing Expertise Both ON Helix and Genesis leveraged the benefits of having a digital component with one hour Innovation Workshops around the conference. The Innovation Workshops, led by experts from the One Nucleus network delivered educational sessions on business, operations and technology topics with insights into international ecosystems. The full list of topics covered in 2021 is below and all sessions are available to watch on-demand. International • Alternative Listing Venues - Have You Thought About Asia? • Accelerating Market Access for Digital Health Innovation between Québec and UK • Learn about the Latest Japanese Startup Ecosystem • Hong Kong Biomedical Cluster and Leading IPO Center in Asia Drug Discovery • Data Inspired Medicines Design • Then and Now – Delivering a Successful Therapeutic to Patients • Demonstration of CDD Vault for Accelerating Drug Discovery Drug Development • Improving Patient Outcome with Better Clinical Data Interoperability • Data Protection in Clinical Trials Regulatory • Supporting Innovation Through Regulatory Interactions • How Regulatory Compliance in Medtech Is a Tool for Success • AI in the medical industry – Artificial Hope or Intelligent Solutions? • MedTech and the Internet of Medical Things Business • Navigating Patent Protection and Freedom to Operate for Antibody Technologies • Getting Investment or Deal Ready- How to Prepare for IP Due Diligence • How Does Real Estate Facilitate the Growth of the Life Sciences Sector? • Solving Scientific Talent Gaps: Stories Behind the Attraction & Retention MedTech • Five Trends Reshaping the Future of MedTech • The Impact of the Covid Pandemic on Healthcare Innovation
www.onenucleus.com | 17
Enabling a Healthier World Biologics
Speed Guaranteed
*
Ibex® Design offers a unique guarantee* of speed and quantity for a fixed price. • 5 months from DNA to Tox drug substance • 11 months from DNA to IND • Minimum 1.5 kg GMP drug substance for your phase 1 clinical trials *For
antibodies. From transfection. Subject to terms and conditions.
18 | One Nucleus Annual Review & Directory 2021/2022
pharma.lonza.com
Meet the Team
Tony Jones
Chief Executive Officer
Debbie Flicos
Finance & Systems Administrator
Alicia Gailliez
Richard Dickinson
Chief Technical Specialist
Laura Bacchus Events & Data Administrator
Claire Abrams
Business Development Manager
Director of Events & Communications
Natalie Keuroghlian
Andrew Bickerton
Marketing Manager
Jean
Chief Operating Officer
Aline Charpentier
Head of Innovation Support
Jasmin Bannister
Events & Communications Administrator
CRM Manager
www.onenucleus.com | 19
Corporate Patron
Corporate Sponsors
20 | One Nucleus Annual Review & Directory 2022/2023
Our Corporate Patron
One Nucleus is delighted that AstraZeneca will continue its long-held relationship as Corporate Patron. For over a decade AstraZeneca has provided significant strategic advice from employees in a variety of departments and roles to help steer our activities. Highlighting AstraZeneca’s commitment to the partnership with One Nucleus, it is our pleasure to have Penny James, Chief Operating Officer, BioPharmaceuticals R&D as a NonExecutive Director. The breadth of this engagement means we have formed a strong and productive relationship with AstraZeneca, based on shared ambitions for the Cambridge and wider UK life sciences community. Accommodating over 2,200 research scientists nothing illustrates AstraZeneca’s commitment to the region’s life science cluster more clearly that its investment in establishing their new Discovery Centre (DISC). Opened by HRH Prince of Wales in late 2021 the prestigious facility epitomises the future of life science R&D; technologyenabled, collaborative and patient-centric. One Nucleus shares this ambition for the cluster to be the world-leading bioinnovator. One Nucleus strives to enable knowledge sharing on the latest innovations in the scientific, business and investment aspects of the sector. AstraZeneca’s willingness to dedicate resource to us, such as event speakers and updates, significantly enhances our ability to share and debate content across areas including R&D, deal making and sustainability. Their engagement provides insight to the nascent companies, their founding entrepreneurs and investors, on how exceptional scientific innovation can be translated into patient benefit globally. This fits well with the collective aspirations of our cluster’s ecosystem; to create life changing technologies and products that have a global impact on lives. AstraZeneca’s role as a global leader and regional champion, in terms of science and societal impact includes their local engagement in mentoring-style schemes and strong practices on environment and diversity, exemplifying the aspirations of the cluster and One Nucleus’s desire to promote the region as the best place for life science talent to work, live and collaborate. Tony Jones, CEO
www.onenucleus.com | 21
One Nucleus Partners Babraham Research Campus
Partner Programme The One Nucleus Partner Programme offers a fully integrated value proposition to organisations seeking to play an influential and visible role in the development of the One Nucleus life science community.
Relationship Management: Each Partner has a tailored Annual Engagement Plan, developed to ensure a good strategic fit with the Partner’s goals for the year ahead and against which performance can be managed. There is an allocated One Nucleus account manager for each relationship to ensure regular reviews and discuss desired adjustments as the year progresses. Engagement may include benefits from the menu below, but the agreed package is designed with flexibility in mind. Partner Benefits: • One Nucleus Gold Membership. • Company logo displayed with advised url hyperlink on the One Nucleus website. • Company logo and url hyperlink in the One Nucleus Annual Review. • Opportunity to speak at One Nucleus events (based on relevance and experience). • Contribution of thought leadership articles to One Nucleus publications. • Placement of a banner advertisement and article in an edition of One Nucleus eNews. • Option to develop bespoke event(s) or workshop(s) to be delivered with One Nucleus. • Three digital delegate passes to any One Nucleus conference offering such an option. • One in-person delegate pass to any One Nucleus conference offering such an option. • Annual 1-2-1 meeting with the CEO of One Nucleus to discuss issues facing the life science sector and possible One Nucleus interventions. • Priority invitation to any VIP-only events hosted by One Nucleus. * To become a One Nucleus Partner the cost is £8,390 +VAT per annum
For information:
+44(0)1223 896450
info@onenucleus.com
www.onenucleus.com
23 | One Nucleus Annual Review & Directory 2020/2021
A CONNECTED
SCIENCE AND TECH E CO SYS T E M
Flexible, secure lab and office space for startup, scaleup and established life science businesses available at locations across Cambridge, Cheshire, Manchester and Birmingham. Join our sector-specialist community to access finance, talent and new markets via our unrivalled partner network.
MELBOURN SCIENCE PARK CITYLABS | MANCHESTER SCIENCE PARK ALDERLEY PARK | BIRMINGHAM HEALTH INNOVATION CAMPUS
CONTACT US TO FIND OUT MORE: HELLO.SCITECH@BRUNTWOOD.CO.UK BRUNTWOOD.CO.UK/SCITECH
Did You Know as a Member You Can...? Connect via groups in the EU, North America, Australasia & Asia
Post job vacancies online
Access the on-demand library of debates and information
Save more than your membership fee via member discounts
As a member you can...
Access the Learning & Development centre for your team
Be seen as an employer of choice
Raise your company’s profile
Network with investors, collaborators and customers
Do get in touch to learn more about membership benefits and how to maximise the return on your investment. www.onenucleus.com | 25
Membership Benefits Benefit
Gold
Silver
Non-member
Listed in online membership directory
Yes
Yes
No
Listed in One Nucleus Annual Review
Yes
Yes
No
Post news to website and social media
Yes
Yes
£75 + VAT*
Advertise jobs on web site
Free
Free
£75 + VAT*
Advertise events on web site
Free
Free
£75 + VAT*
ON Helix In-Person Delegate 2022
£295 + VAT
£395 + VAT
£495 + VAT
ON Helix Digital Delegate 2022
1 Comp Pass/member Extras £35 + VAT
1 Comp Pass/member Extras £50 + VAT
£75 + VAT
Genesis In-Person Delegate 2022
£295 + VAT
£395 + VAT
£495 + VAT
Genesis Digital Delegate 2022
1 Comp Pass/member Extras £35 + VAT
1 Comp Pass/member Extras £50 + VAT
£75 + VAT
BioWednesdays
Free
Free
£50 + VAT
A4 Advert in eNews
£500 + VAT
£500 + VAT
£800 + VAT
Innovation Seminars
Free
Free
Invitation Only
Training
30% discount
15% discount
List Price
Facilities Management Consultancy Day Rate
£700 plus expenses + VAT
£850 plus expenses + VAT
£1,000 plus expenses + VAT
Preferred Supplier Discounts
Yes
Yes**
No
Access M2M Marketplace discounts
Yes
Yes
No
Access to Themed Interest Groups
Yes
Yes**
No
Employer of Choice Sessions
Free
Free
Invitation Only
Access to on-demand library
Yes
Yes
Restricted
* NEW! Non members can now advertise jobs, news and events on our website at rates shown **Access to some but not all 26 | One Nucleus Annual Review & Directory 2022/2023
Member Savings
Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. One Nucleus negotiates savings and discounts for members by leveraging the critical mass of our membership, providing members with the purchasing power of a large entity. Receive discounted rates on laboratory supplies, services, key industry events and more.
Make Even More Savings with the One Nucleus Group Purchasing Scheme • Gold members can benefit from 10 Preferred Supplier contracts. • NEW! Silver members can now access 5 Preferred Supplier contracts. • NEW! 3 new contracts awarded for our members in 2021. • 001 - utility savings and green energy contracts • Circular1 Health - COVID testing • Research Solutions Inc - scientific literature services. • Saving members over £4 million per annum on a combined spend of £7 million per annum. • Member retains full control over their own procurement, which is key to R&D operations. • Member has direct relationships with the suppliers, including access to services which are customised to their needs. • Gold Members using Fisher Scientific receive a growth rebate on their annual spending at the end of the year - rebate in 2021 was 5.5%. The overall savings made, easily cover the cost of a Gold Membership. • All Preferred Suppliers have published sustainability plans and policies to protect customers’ environmental footprint.
www.onenucleus.com | 27
Member Savings Member to Member Marketplace: • •
Convenient destination to find an array of discounted products and services. 19 Support Suppliers offering discounts to One Nucleus members.
Events: • A free Digital Delegate Pass for each One Nucleus member company to ON Helix and Genesis. A combined saving of £150 + VAT over non-members. • Discounted delegate rates at ON Helix and Genesis for in-person or additional digital delegates. • A range of discounts at international and national industry partnering events and conferences such as BIO-Europe Spring, BioTrinity, AngloNordic Conference, BioIntegrates, BIO Convention, Medi-Integrates, NLSDays and Bio-Europe.
Facilities Management: •
•
Accessing expertise - Our Chief Technical Specialist, Richard Dickinson, has over 25 years’ experience as a Facilities Manager. Provision of project management for office and laboratory fit-outs and can assist with laboratory service contracts, maintenance contracts, cleaning contracts, utility bills, insurance, purchasing and budgeting. Daily Rates (excluding VAT) – Gold members £700 plus expenses; Silver £850 plus expenses; Non-member £1,000 plus expenses. View case studies.
•
Contact Richard Dickinson to discuss your needs and secure a quote.
•
•
28 | One Nucleus Annual Review & Directory 2022/2023
Member Savings in 2021 The chart below is a snapshot of our members, ranging from extra large to micro and demonstrates the savings made by them using the Purchasing Scheme. For some, the rebate alone covered the cost of membership.
Full price Purchasing scheme price Rebate Cost of membership
Extra Large
£1,494,417 £901,246
39% saving
£56,500 £7,630
Large
£331,881 £202,337
39% saving
£8,100 £5,025
Medium
£255,831 £154,875
39% saving
£7,807 £3,230
Small
£505,309 £305,272
40% saving
£18,600 £1,240
Micro
£189,194 £115,759 £9,200
39% saving
£730
www.onenucleus.com | 29
Facilities Management Facilities management can be a real problem for small technology companies with challenging demands for laboratory, workshop and office space. One Nucleus provides a range of Facilities Management Services to help our member companies to expand or relocate. We provide project management for office and laboratory fit-outs (no job too small), help with laboratory service contracts, maintenance contracts, cleaning contracts, utility bills, insurance, purchasing and budgeting. As with all our services, these are provided at discounted rates to our members. Our Facilities Management Services and Purchasing Scheme are managed by Richard Dickinson, One Nucleus’ Chief Technical Specialist, who has more than 25 years’ experience in laboratory and facilities management. Richard has extensive local contacts and is also NEBOSH certified in health and safety. Recent projects and clients include: • Alchemab Therapeutics Ltd • Broken String Biosciences Ltd • Cambridge Epigenetix Ltd • Charm Therapeutics Ltd • Clover BioPharmaceuticals UK Ltd • Healx Ltd • Nuclera Nucleics Ltd • Summit Oxford Ltd • Superdielectrics Ltd • VaxEquity Ltd Companies Richard has helped this year have a total of 166,500 sq. ft. of space.
30 | One Nucleus Annual Review & Directory 2022/2023
Partner with the world leader in serving science Join the Jump Start New Lab Program The Jump Start partnership program is designed to support new and expanding labs with the tools and resources needed to accelerate research and achieve the next milestone. Join today and we will partner with you through all aspects of starting or expanding your lab including: • Discounts of up to 50%* on scalable and innovative life sciences equipment, instruments and consumables • Personalised lab design support using virtual reality • Regulatory and compliance guidance and support • Flexible finance solutions including leasing options
You are eligible for the Jump Start New Lab Program if you are: • Opening a new lab within your institution or company • Expanding your existing lab • Moving your lab to a new space • Starting a new company
Learn more at thermofisher.com/obnjumpstart For Research Use Only. Not for use in diagnostic procedures. © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. *Terms and conditions apply. Visit: www.thermofisher.com/jumpstart for full details. COL017771 0122
EAST OF ENGLAND DEAL MAKING ACTIVITY The East of England is a vibrant hub for biotech and life sciences. Home to more than 200 research institutions, biotech start ups and SMEs, the East of England continues to go from strength to strength. Fundraising has been traditionally in the spotlight; however, the deal making activity and the type of transactions that take place are equally important. Deals are a good indication of the innovation that takes place in this region and its impact. During the last 2 years (2020 & 2021), 143 companies and research institutions in the East of England have disclosed 251 deals collectively1. Despite a small decline compared to the previous year, the 2021 deal activity in the East of England remained at high levels. 2021 saw 119 disclosed deals, a 10% decline in deal making comparing to the 132 disclosed deals of 2020. The number of transactions remained relatively stable throughout 2021. Q1, Q2 and Q4 recorded 31 deals each while Q3 witnessed 26 deals. This translates to an average of 30 deals per quarter and is not far from the 2020 average of 33 deals per quarter.
As with 2020, the majority of the 2021 deals comprised Research Collaborations (54.6%), Licensing agreements (15.1%) and Development & Manufacturing agreements (10.9%). However, 2021 saw a clear shift towards Research Collaborations. Research Collaborations increased by 35% year-over-year (YoY) while Licensing and Development & Manufacturing agreements experienced a 48% drop YoY. Company Acquisitions were also noteworthy, almost doubling from 5 (2020) to 9 (2021). Deal Type Research Collaboration License Development & Manufacturing Company Acquisition Co-Development Distribution Agreement Manufacturing & Supply Asset Purchase Merger Joint Venture Co-promotion Fundraising, Research Collaboration & Option to License
1
2020 48 35 25
2021 65 18 13
5 7 4 3 3 n/a 1 n/a 1
9 5 3 n/a n/a 2 2 1 1
Sources: Clarivate Deals Intelligence and Analytics & BiosciDB (accessed on 15/02/2022).
32 | One Nucleus Annual Review & Directory 2022/2023
Deal Type
2020
2021
Research Collaboration
48
65
License
35
18
Development & Manufacturing
25
13
Company Acquisition
5
9
Co-Development
7
5
Distribution Agreement
4
3
Manufacturing & Supply
3
n/a
Asset Purchase
3
n/a
n/a
2
Joint Venture
1
2
Co-promotion
n/a
1
1
1
Merger
Fundraising, Research Collaboration & Option to License
Research Collaborations The vast majority of the 2021 Research Collaborations came without a disclosed commercial component – only 11% (7/65) disclosed a license or an option to license at a later stage. Besides an increase in the total number of Research Collaboration deals, 2021 saw a substantial increase in the number of Research Collaborations that involved preclinical assets (2.3-fold increase) and assets in clinical trials (6-fold increase) compared to 2020. The clear front runners in terms of therapeutic areas were cancer and infectious diseases. Cancer deals more than doubled comparing YoY (34 vs 13) and accounted for 52% of the Research Collaborations. On the other hand, Research Collaborations for Infectious Diseases remained relatively stable between the two years (17 vs 14). Unsurprisingly, the Infectious Disease collaborations revolved almost exclusively around COVID-19 (>90% of the Infectious Disease Research Collaborations in both years); a trend that reflects the effect of the pandemic and the urgency for research and innovation. The majority of the Infectious Disease Research Collaborations related to therapeutics – especially in 2021 – and comprised mainly research on New Molecular Entities instead of repurposing compounds.
* Other refers to assets at an undisclosed stage of development, agreements for basic research (sample testing, biomarker research, target validation, etc.), and collaborations around platform technologies (AI applications, screening platforms, etc.).
www.onenucleus.com | 33
Licensing Agreements
Licensing deals experienced the biggest drop YoY among the different types of deals (48.6% drop). Licensing deals in 2021 displayed a decrease in both absolute numbers and diversity. 18 deals were struck in 2021, of which 17 referred to drugs and 1 to a companion diagnostic. In comparison, 2020 saw 35 licensing deals; 29 referred to drugs while the remaining included diagnostics, expression platforms, drug delivery technology, cell conversion technology and sequencing technology.
Assets at an earlier stage of development (Discovery & Preclinical) were generally favoured across both years. A good number of licensing deals involved launched products in 2020 (4 deals) however, this trend did not follow up in 2021 (1 launched product deal). Cancer and Infectious Diseases were the prevalent therapeutic areas for Licensing deals as well.
Partner Country of Origin
Companies from the East of England tend to find themselves on the science/technology originator side rather than the commercial partner, which is the case for approx. 58% of the deals in both 2020 and 2021. When looking exclusively at the licensing and asset purchase deals, this percentage increases to 63% and 61% for 2020 and 2021 respectively, supporting the value of the East of England as an innovation hub. The innovation taking place in this region attracts both foreign and domestic partners. UK-based companies appear to be the main type of partner for 2021, representing 36% of the overall deal activity, a 2% increase from 2020’s 34%. The USA is a close second (31% of 2021 deals; 36% of 2020 deals) and represents the biggest pool for overseas partners. The remaining partners are widespread and stretch from Canada and Europe all the way to Asian markets such as Japan and China.
34 | One Nucleus Annual Review & Directory 2022/2023
Deal Financials
Out of the 119 deals for 2021, only 17 had financial details disclosed. These deals span research collaborations, licenses, asset purchases, co-development agreements, fundraising and company acquisitions, and could amount to more than $21 BN (~£15.6 BN) including contingent milestones. The median deal size in 2021 stood at $1.2 BN (£890 M) with a balanced split between upfront and milestone payments. The considerations paid included both cash and equity. All Deals 2021 Total Deal Size ($M)
Upfront ($M)
Milestones ($M)
Median
1,190.5
300.5
227.5
Average
1,241.5
920.5
733.8
Min
17.0
12.0
8.0
Max
7,200.0
7,200.0
2,600.0
Upper Quartile
1,400.0
1,025.0
1,062.5
Lower Quartile
300.7
18.1
56.0
17
14
6
n
2021 Licensing agreements with financials disclosed had a median deal size of $68.3 M (~£51 M) and were backloaded with most of the payments tied to development and regulatory milestones – milestone payments outweighed upfront payments by almost 4:1. Company acquisitions had a different deal structure, with most of the value coming as upfront, as expected. Milestones/ Contingent consideration were less frequent and when present represented a fraction of the total deal size (13-24%). Research Collaborations came with a hefty deal size but they found themselves on the other end of the deal structure spectrum, with almost all of the value tied to development and regulatory milestones. Research Collaborations in 2021 saw milestone payments outweigh upfront payments by 14:1. Licensing Agreements 2021 Total Deal Size ($M)
Upfront ($M)
Milestones ($M)
Median
68.3
14.0
56.5
Average
116.4
14.3
56.5
4
3
2
n
Company Acquisitions 2021 Total Deal Size ($M)
Upfront ($M)
Milestones ($M)
Median
1,295.3
950.0
194.9
Average
1,724.5
1,588.3
194.9
8
8
2
n
Research Collaborations 2021 Total Deal Size ($M)
Upfront ($M)
Milestones ($M)
Median
1,320.0
18.8
1,316.3
Average
940.0
18.8
1,316.3
3
2
2
n
Conclusion
The East of England is very active in deal making, especially in the fields of Cancer and Infectious Diseases. Companies in the East of England are at the forefront of innovation and attract partners from all over the world. Activity has remained high despite the pandemic and in certain cases has been even fueled by it. Q1 2022 is not complete yet but more than 30 deals have already taken place in the East of England, suggesting that 2022 will be another prolific year for deal making.
Kyriakos Tzafestas Ph.D. - Associate | PharmaVentures Ltd www.onenucleus.com | 35
ZONE 2 RENDERING
Locate Your Business at the Centre of Science Zone 2 is a new ~240,000 SF three-building development located on a best-in-class science park in Cambridge, Granta Park. Granta Park is an inspirational 120 acre estate that perfectly captures the essence of Cambridge and the life sciences community with beautiful, green surroundings, creating the ultimate environment for a work-life balance. GRANTA PARK
www.grantapark.co.uk
BioMed Realty, a Blackstone portfolio company, is a leading provider of real estate solutions to the life sciences and technology industries.
Providing Space for the Pioneers of Life Sciences As a world-leading developer, owner and operator of mission critical real estate solutions for the life sciences and technology industries, we’re proud to have a strong presence in both Cambridge, MA, and Cambridge, UK. In these vibrant ecosystems, the innovators and enterprising companies to whom we provide the necessary space to thrive, are in search of accelerating breakthroughs that seek to solve the biggest healthcare and bioscience challenges of our age. They need the right assortment of equipment, but also curated laboratory and office environments to succeed — and it is these ingredients which we offer to the hundreds of tenant partners across our trans-Atlantic portfolio. Because innovation happens in proximity, not in isolation, life sciences hubs thrive by having access to a large talent pool, nearby academic and research institutions and close proximity to venture capital and other investors. The UK life sciences ecosystem not only has these key elements, but is also fueled by the growth in tenant demand underpinned by funding into the sector. Of the 13.7 million square feet of research and workspace BioMed owns and operates in the UK and US, approximately one million square feet is in Cambridge, UK. This space is all fully leased, having recently welcomed two pioneering companies – Altos Labs and Bicycle Therapeutics – to our recently renovated Portway building at Granta Park, one of the largest purpose-built life sciences developments in the Oxford-Cambridge Arc and home to over 30 of the world’s largest life sciences companies and research organizations, including Pfizer, Illumina and Cancer Research UK. This represents a formidable cluster of collaboration and innovation that employs more than 3,700 people. In addition to the 13.7 million square feet of operational space, BioMed maintains a premier development platform with 3.5 million square feet of Class A properties in active construction. To extend the runway of supply for the burgeoning life science sector globally, we’re also actively looking for ways to continue expanding this pipeline in all our key markets — including the UK — as represented by last year’s announcement that we intend to nearly double the size of our portfolio in Cambridge. Our best-in-class portfolio, market-leading platform and growing pipeline allows us to meet rapidly increasing demand in the UK. The UK life sciences industry is world-leading and life-saving, as the Oxford University and AstraZeneca COVID-19 vaccine demonstrated. The UK has consistently had strong government funding into the sector, with UK government spending on healthcare and R+D the highest in Europe and second in the world. But it is not only the convergence of academic ties, government support and private investment that life sciences companies need. The pandemic has shown that some industries can operate successfully with remote workers, but essential lab work for drug discovery cannot be done from home. It requires highly specialized research and workspace. Having the right building in the right location is just as important as having the right talent. Bill Kane, President - East Coast & UK Markets, BioMed Realty www.biomedrealty.com www.onenucleus.com | 37
Success is our science The life sciences sector is hugely innovative but also highly complex and regulated. Our renowned multi-disciplinary team of lawyers have deep sector knowledge and can help wherever you need, whether that is to protect your latest idea, to execute complex transactions or deal with compliance issues. We provide the solutions to enable you to seize the opportunities open to you.
To find out more, please contact: James Fry Partner and Head of Life sciences james.fry@mills-reeve.com
www.mills-reeve.com
Increasing Sophistication in the Pharma/ Biotech Partnership Model The last couple of years have seen the life sciences industry propelled into the mainstream news. Advanced technologies like mRNA vaccines and novel antivirals have received unprecedented public attention, and for good reason as the sector provides a powerful toolkit to respond to the global challenge of the COVID-19 pandemic. Investment in the sector has been strong with reports of 2021 surpassing previous records for fundraising for UK life sciences and biotech companies, reaching some £4.5bn. This will support and drive forward continuing innovation Teamed with exceptional levels of investment, we are also seeing increased activity amongst peer-to-peer dealmakers in the sector. Biotech companies with strong proprietary technologies can offer new routes to tackling unmet need alongside more tried and tested approaches to drug discovery. This dynamic can shift the power balance in favour of the smaller partner, which enable it to retain more control over the applications for its technology. Important strands for a biotech partner include the following points. Define carefully the scope and extent of each licence. While licences in the past might have been broadly cast to allow a wide range of activity and target-seeking on the part of the licensee, there is now greater sophistication in the allocation of fields of activity between technology users. In addition to helping the biotech innovator to realise full value for its technology, it also enhances the likelihood that important patient benefits will be realised across a broad range of needs. A licensee will focus R&D effort on its own areas of interest, leaving neighbouring fields to be taken forward by others. Mechanisms to make this work include gatekeeper arrangements that serve both to protect the biotech’s in house programmes and those of all of its licensees. Identify and retain control of fields for in-house R&D. We are seeing biotech innovators select fields that will be reserved for in-house R&D. While biotech companies may in the past have left drug discovery and development to major players with an international presence and well-resourced development machine, many now see carefully defined projects as a part of their own remit. If progressed effectively, these can offer an important potential source of revenue. The high risk profile of in-house development can be offset by revenue streams from out-licensing in other areas. Consider per-target pricing models. Biotech companies are increasingly looking at pricing that is based on the number of targets that a partner will select and take forward using the licensed technology. Where a particular target does not progress well, a replacement mechanism is usually appropriate. However, retaining control over the ultimate number of projects helps the biotech provider to realise full value from its technology. The different shape and character of any particular collaboration will determine the extent to which these considerations apply, but we see these factors coming into play across many types of activity. James Fry, Mills & Reeve www.mills-reeve.com www.onenucleus.com | 39
Fast, flexible, sterile fill-finish service specifically designed to meet the needs of clinical trials.
Cambridge, UK
+44 1223 736320 info@cambridgepharma.com
In-house expertise to support novel drug development including process development, QC analysis & stability studies. © 2022 Cambridge Pharma Limited All rights reserved.
40 | One Nucleus Annual Review & Directory 2021/2022
It takes a Network… More than a membership organisation, One Nucleus is a network with many ways in which to interact and draw benefit from it. Think of it as a social group with a nucleus of core elements which would be active in managing the activities and working on maintaining the connections – this would be your devoted One Nucleus team! – the other elements of the group would then interact as much, or as little as they wanted but sharing a common goal. For the social group it could be as simple as having fun, and for a group like One Nucleus it is to leverage collective strength and intelligence to progress their business, career or product development. As there is no better place than the Annual Review feature to reflect on this network as a whole, here is a representation of the One Nucleus network and importantly, our valuable members. Introducing One Nucleus membership There are numerous reasons for becoming a One Nucleus member including profiling opportunities, making new contacts, sharing and learning with peers, or saving money with our purchasing scheme, but there is always one common factor: the contribution to the life science innovation value chain. This value chain, ranging from public research institutions to large drug developers with all stages of company in between, is fully represented in the One Nucleus membership accounting for 31% of its total. The discovery and development backbone could not deliver on its promise without the increasingly specialised support from technology providers representing another 30% of the network and ranging from niche technical services in data, chemistry or biology to broad spectrum CROs and CDMOs. The rest of the support is a highly specialised group of professional services helping companies operations as well as their strategic development.
Here is a more detailed representation of One Nucleus members with examples. The breadth of expertise and span of company size is a great reflection of the wider One Nucleus community and one of the keys for the network success.
www.onenucleus.com | 41
It takes a Network…
Understanding the regional dynamic The One Nucleus membership ecosystem does not exist in isolation, but sits within the surrounding cluster centred on Cambridge; the two sharing a very symbiotic relationship. Not all of its geographic neighbours, whether public or private organisations, will be One Nucleus members at any given point. The value of membership being dependent on their status, activity plans or employees’ availability to engage. Importantly, One Nucleus maintains comprehensive connectivity with, and awareness of, the whole ecosystem. Our understanding of the whole, not just our members with our flexible approach to engaging non-members, makes One Nucleus the go-to network for the region.
Breakdown of Therapeutics Biotech in East of England
42 | One Nucleus Annual Review & Directory 2022/2023
Laboratory Services
If you’re relocating your laboratory, Restore Harrow Green are the experts you can trust to handle every aspect of your project. Our advanced knowledge of laboratory operations means we are able to handle: Samples, and chemicals, including dangerous & hazardous goods All types & sizes of moves, specialising in complicated projects Instruments and all types of equipment Cold chain materials IT, data and archives Clean Rooms Office, write up, and break out areas Glasg
ow
We provide: A high Level of Service & Technical ability
Manc
heste r
Leed
s
A dedicated Lab Project Manager An in-house DGSA
Birm
ingha
Bristo
m
l
We have branches in every major UK city and can undertake any size lab move. We also store and distribute all types of equipment. In addition, our new, lab dedicated facility in Cambridge, was purpose built to support the area’s research parks and wider scientific community.
Camb
ridge
Lond
on
Contact us today to discuss your project an d to book your free consultatio n
We guarantee: Your peace of mind! www.harrowgreen.com RHG Laboratory Services
@HarrowGreen
labprojects@restore-harrowgreen.com 0345 603 8774
www.onenucleus.com | 43
It takes a Network… This breakdown is a good reflection of the key technology expertise in the East of England region. Not only are most of these companies at the cutting edge of their science topic but they are also active deal makers, as analysed in the article ‘East of England’ deal activity on page 32 of this Review. In conclusion there are many ways to interact with the One Nucleus community, but it always has to start by acknowledging this community - it encompasses both members and the wider network. The annual review is a good place to start with the following A- Z list of members. In describing the network, the aim is to illustrate One Nucleus’ role in helping all stakeholders to solve the ‘big challenges’; generating the best biotech innovations, developing the best treatments and being the best life sciences cluster.
International Connections for Local Benefits With Life sciences being a truly global sector, international connectivity is vital. Set out below are some key international facing activities One Nucleus undertakes. Leveraging international conferences Events like BioEurope or BIO are great opportunities for life science companies to make connections and develop their international footprint. Through our collaboration with EBD group and other conference providers, One Nucleus secures significant discounts on registration fees for its members. Bringing the rest of the world to us Understanding the life science sector characteristics of other geographical locations is also an important component of international business development. Governments can provide effective overviews and key data but hearing directly from those within an ecosystem often provides more practical insight. We are very privileged at One Nucleus to have a fantastic network of international bioregions, represented below, who are willing to engage in our activities and interact with the One Nucleus network.
Examples of sessions at Genesis 2021 to highlight and connect key international One Nucleus partners included:
Accelerating Market Access for Digital Health Innovation between Québec and UK Learn about the Latest Japanese Startup Ecosystem Hong Kong Biomedical Cluster and Leading IPO Center in Asia
44 | One Nucleus Annual Review & Directory 2022/2023
It takes a Network… Looking to 2022, we’ll get back to hosting in-person international delegations so watch this space as your next international partner may come to your doorstep. Building a consortium to better support our network The latest addition to our toolbox to support our members, is a consortium involving One Nucleus, BioCat in Barcelona, STUNS in Uppsala, CHealth in Estonia and Eurasante in Lille to support life science companies on their digitalisation journey. Digitalisation is not new, but is revealing some very sector-specific challenges when bringing sophisticated data technologies and skills to highly established and regulated industries. These challenges are not simply a UK matter and members do not just look domestically. To learn from expertise in other geographies, and develop effective new support offers for our members, One Nucleus has entered a new EU-funded project entitled BRIGHT. Working with Biocat (Barcelona), STUNS (Uppsala), CHealth (Estonia) and Eurasante (Lille), the programme will map and compare the common challenges and develop services to address support gaps whilst developing close connections with these leading European life science and digital hubs. Connections we can share with our members. This opportunity would never have been available without our involvement in the Council of European BioRegions, a European network of bioclusters. The group enables the development of relationships with key contacts in various parts of Europe. It acts as a forum for exchanging good practice in supporting life science and healthcare companies. It reinforces our view that it takes a global vision to be a good local supporter! To discuss these international opportunities, please contact Aline: aline@onenucleus.com
Your employees are your most valuable asset, and training is an investment in the future of your business. Register your employees for a One Nucleus Training Course today.
Up to 30% off Training Courses for One Nucleus Members
Courses include: • Introduction to Drug Discovery - From Idea to Clinical Candidate • Biological Safety: Management and Practice • Introduction to Drug Development - From Candidate Selection to Patients in Healthcare • Laboratory Health and Safety • Presentation Skills for Scientists • The Safe Use and Management of Laboratory Gases
Visit onenucleus.com/training-courses to see the list of current training courses we have to offer.
Member A-Z Listing
www.onenucleus.com | 47
A-Z Listing 0-A
ArkVax Limited Artemida Pharma
001 Limited
Artios Pharma Limited
4G Clinical
Asahi Kasei Pharma
A4Pbio
Astellas Pharma Europe Ltd
Abcam plc
Astex Pharmaceuticals Ltd
Abingworth LLP
AstraZeneca
ACellZ Limited
Atelerix Ltd
Actigen Limited
ATG Scientific Ltd
Adaptate Biotherapeutics Limited
Aurigene Pharmaceutical Services Ltd
Adrestia Therapeutics Ltd
Autolus Limited
Advarra
Avacta Life Sciences Ltd
Advent Life Sciences LLP
AZoNetwork UK Ltd
Agenus UK Limited Agility Life Sciences
B
Aglaris
Babraham Institute Enterprise Limited
Air Liquide UK Ltd
Babraham Research Campus Ltd
Air Products PLC
Bactobio
Alchemab Therapeutics Ltd
BBI Cambridge Ltd
Alkamis Pte Ltd
Beacon For Rare Diseases
All Med Pro
Beauchamp Technology
Alloy Therapeutics UK Ltd
BenevolentAI
Alpha MD Limited
BicycleTx Limited
AltemisLab Limited
Bidwells
Amphista Therapeutics Ltd
Bio Transcript Partners LLP
AMS Advanced Medical Services
Biocair - UK
AMS Biotechnology (Europe) Limited (AMSBIO)
BioCity Group Limited
Antikor Biopharma
Biocrucible Ltd
Apollo Scientific Limited
Biofaze Limited
Apollo Therapeutics LLP
Biofidelity Limited
Apple Tree Life Sciences (UK) Limited
BioIVT
Appleyard Lees IP LLP
BioM Biotech Cluster Development GmbH
Aqdot Ltd
BioMed Realty
Arecor Limited
BioNJ
Arise Innovation Centres 48 | One Nucleus Annual Review & Directory 2022/2023
A-Z Listing Bionow
Cancer Research UK (CRUK)
BioPartner UK
Capella Bioscience Limited
BioPharmaLogic LLC
Carocell Bio Limited
Biorbyt Ltd
Catalent Pharma Solutions
BioStrata Marketing
Cellomatics BioSciences Ltd
Biosynergy (Europe) Ltd
Centre for Process Innovation (CPI)
Biotechnology Innovation Organization (BIO)
Cerevance Ltd
bit bio Ltd
Charles Consultants (Life Sciences) Ltd
Blue Link Worldwide UK Limited
Charles River
BOC
Charles Stanley & Co. Limited
Boehringer Ingelheim
Chesterford Research Park
Boult Wade Tennant
Chiesi Limited
Boyds
Child Growth Foundation
Bridge Partners Ltd
CIMYM BioSciences Ltd
Bristows LLP
Cinference UG
Broken String Biosciences Ltd
Clinion UK Ltd
Bruntwood SciTech
Closed Loop Medicine Limited
Business France - Healthcare/Biotech Team
Clover BioPharmaceuticals UK Ltd
C
CMS Cameron McKenna Nabarro Olswang LLP Life Sciences Team
Cambridge Design Partnership LLP
CN Bio Innovations
Cambridge Employment Law LLP
Collaborative Drug Discovery
Cambridge Enterprise Limited
Colorifix Ltd
Cambridge Epigenetix Limited
Compugen - UK
Cambridge Innovation Capital (CIC)
ConcR
Cambridge Network Limited
Congenica Ltd
Cambridge Pharma Limited
Coulter Partners
Cambridge Rare Disease Network (CRDN)
Creative Places LLP
Cambridge Research Biochemicals
Crescendo Biologics
Cambridge Science Park
Cryoniss Ltd
Cambridgeshire Chambers of Commerce
Curileum Discovery Ltd
Camlab Ltd
CW (Cambridge Wireless Ltd)
CAM-SCI
CY Partners Recruitment Limited
Canadian High Commission
Cytocell Limited
www.onenucleus.com | 49
A-Z Listing D
Essen BioScience Ltd ET-traps Limited
D Young & Co LLP
Eurofins Genomics UK Ltd
Deep Science Ventures
Eurofins Selcia Limited
Deliver Plus Limited
Evonetix
Deloitte
Evotec UK Ltd
Demuris Ltd
ExecMind International Executive Search
Diosynvax Ltd (DIOSVax) Discovery Park Limited
F
Discuva Ltd
F.institute - UK
DLRC Ltd
Faron
Domainex Ltd
Fish & Richardson P.C
Dr Clare Sansom Freelance Science Writer
Fisher Scientific UK
Dr. Reddy’s Laboratories (EU) Ltd
Freeline Therapeutics Limited
Drishti Discoveries Limited
F-star Therapeutics Limited
E
Fusion Antibodies PLC
Earlham Institute
G
Eastern AHSN
Gallagher Life Sciences Practice (UK)
EBD Group
GENEWIZ UK Ltd
Educo Life Sciences Limited
Genomics England
EIP
George James Ltd
Eleven Therapeutics (UK) Limited
Giggabox Ltd
Eli Lilly
Goodwin - UK
Elixa MediScience Ltd
Government of Québec
Ellarion Cybernetics Ltd
Greenleaf Processing Ltd
Eagle Genomics Ltd
Embassy of Switzerland Emberion Limited
H
EMBL-EBI
Harlow Council
Empyrean Therapeutics Ltd
Harts Business Solutions - Bluefish Office Products
Enedra Therapeutics Limited
Ltd
Enplas (Europe) Limited
HC Pharma Consultancy Limited
Epitopea Ltd
Health and Safety Works Ltd
ERA Consulting (UK) Ltd
Health Enterprise East
Ernst & Young LLP (EY)
Hide Biotech Limited
50 | One Nucleus Annual Review & Directory 2022/2023
A-Z Listing Highbury Regulatory Science Limited
K
Histocyte Laboratories Ltd
Kantify
Howard Ventures Ltd
Kao Data
HungaroTrial CRO - UK
Kathryn Simpson Consulting Limited
Healx Ltd
Kelyon
Hide Biotech Limited
King’s College London (KCL)
Highbury Regulatory Science Limited
KISS Communications
Higher Steaks Ltd
KPMG LLP (Life Sciences)
Histocyte Laboratories Ltd Horizon Discovery Ltd
L
Hoxton Farms Limited
Labcorp Early Development Laboratories Ltd -
Hyper Recruitment Solutions (HRS)
Alconbury Latham & Watkins
I
Leaf Expression Systems
Illumina Cambridge Ltd
LEX Diagnostics Limited
Immodulon Therapeutics
LifeArc
Independent - Martino Picardo
Lifesci Search Limited
Independent - Miranda Weston-Smith
LifeSciences British Columbia
Infex Therapeutics Limited
Lightox Limited
Infinity BiologiX Limited
LINK-J (Life Science Innovation Network Japan, Inc)
Inivata Limited
Locki Therapeutics Limited
Innomech Ltd
London BioScience Innovation Centre (LBIC)
Innovate UK
London Stansted Cambridge Consortium (LSCC)
Instinctif Partners (Life Sciences)
Lonza Biologics Plc
IONTAS Ltd
Luna Therapeutics Ltd
iosBio Ltd IP Pragmatics Limited Isomerase Therapeutics Ltd
M Macfarlan Smith (Cambridge)
J
Macomics Limited
J A Kemp LLP
Mandeville Technology Limited
Johnson & Johnson Innovation (JnJ)
Marks & Clerk Mathys & Squire LLP Maxion Therapeutics Limited MedCity www.onenucleus.com | 51
A-Z Listing M
MSD
Medical Research Council (MRC)
Mursla Limited
Mercury Bioscience Consultants Ltd
MyData-T LTD
Mestag Therapeutics Limited
Murray International Partners Ltd
MetalloBio Limited
N
Metrion Biosciences
Nabalu Pharma Services Limited
Mewburn Ellis LLP
Nanna Therapeutics Ltd
Mi3 Limited
National Physical Laboratory
Microbiotica
Nationwide Laboratories
MicrosensDx Ltd
Nbbj
Mills & Reeve LLP
NeoGenomics Laboratories, Inc
Mind Over Cancer
NeRRe Therapeutics Limited
MIP Diagnostics Ltd
Neuroservices-Alliance
Mission Therapeutics Limited
New England Biolabs (UK) Ltd
Mogrify Limited
New Path Molecular Research Limited
Monument Therapeutics Limited
New Scientist
MSD
Newcastle BioSphere
MultiplAI Health
Newcells Biotech Ltd
Murray International Partners Ltd
Nexcelom BioScience Ltd
Mursla Limited
Nexus Intelligent Engineering
MyData-T Ltd
NNEdPro
Myricx Pharma Ltd
Norwich Research Park
Mercury Bioscience Consultants Ltd
Novogene (UK) Company Ltd
Mestag Therapeutics Limited
Nuclera Nucleics Ltd
Metrion Biosciences Mewburn Ellis LLP
O
Microbiotica
o2h Ltd
MicrosensDx Ltd
Oak Zone Biotech UK Limited
Mills & Reeve LLP
Ocean Bio Limited
MIP Diagnostics Ltd
Odgers Berndtson
Mission Therapeutics Limited
OMass Therapeutics
Mitsubishi Tanabe Pharma Corporation
OncoLytika Ltd
Mogrify Limited
One Nucleus
Monument Therapeutics Limited
Onyva the Agency
52 | One Nucleus Annual Review & Directory 2022/2023
A-Z Listing Oppilotech Ltd
Q
Optimum Strategic Communications
QMS Consultancy Ltd
Origin Sciences Limited
QRC Consultants Ltd
Osborne Clarke
Quadram Institute Bioscience
Oxford Nanopore Technologies Plc
Queen Mary BioEnterprises Ltd
Oyster Venture Partners Limited (OVP)
Queen Mary Innovation Ltd Queen Mary University of London (Business
P
Development)
Parkinson’s Concierge
Quotient Sciences Ltd
Partners& - Life Science Insurance PCI Pharma Services
R
PCML
Rare Biotech Ltd
PCR Bio Systems Limited
Reading Scientific Services Ltd (RSSL)
Penningtons Manches Cooper LLP
Reddie & Grose LLP
PeproTech EC Ltd
Reed Scientific
Pharma International
Release Life Sciences and Diagnostics Ltd (RLS)
PharmaGuide Ltd
Restore Harrow Green
PharmaLex UK
Richmond Pharmacology Ltd
PharmaMedic Consultancy Limited
RiverRhee Consulting
Pharmaron UK Ltd
Roslin Cell Therapies Limited
PharmaVentures Ltd PharmEnable Limited
S
Phico Therapeutics Ltd
Sagittarius IP
PhoreMost Ltd
Salve Therapeutics Inc
Photography for Healthcare & Biotech
Scendea Ltd
PiR International
Scitribe Consulting Limited
PPMLD Ltd
Semarion Limited
Precision BioSearch Limited
Sense Biodetection Ltd
Precision for Medicine - UK group
Shionogi B.V.
Precisionlife Ltd
Simcere UK Limited
ProductLife Ltd
Singular Talent Limited
ProPharma Partners Limited
SIP Cambridge
Protogenia Consulting Ltd
Sky Bio Ltd Somaserve Ltd Sookio Limited www.onenucleus.com | 53
A-Z Listing Sosei Heptares - Cambridge St John’s Innovation Centre Ltd
U
Standigm UK Co Ltd
UK Health Security Agency (UKHSA)
STARLAB (UK) Ltd
UKSPA
Start Codon Ltd
University College London - SysMIC
STEMCELL Technologies UK Ltd
University College London (UCL)
Stevenage Bioscience Catalyst
University of Cambridge
Storm Therapeutics Ltd
University of East Anglia (UEA)
Stratosvir Limited
University of Essex - Research and Enterprise Office
Sue Rees Associates
University of Leicester- Enterprise & Business
Superdielectrics Ltd
Development Office
Swift Molecular Diagnostics Limited
University of Nottingham - Corporate Partnerships
Sygnature Discovery Ltd
V
T
ValiRx Plc
Talisman Therapeutics Ltd
VaxEquity Ltd
Talwarbio Limited
Vector Laboratories Ltd
Taylor Vinters
VectorBuilder Inc
Taylor Wessing
Venner Shipley LLP
The Brain Tumour Charity
Vernalis Ltd
The Cambridge Crystallographic Data Centre
VirdisGroup Ltd
(CCDC)
Vitrolife
The Communications Strategy Group Inc. The Institute of Cancer Research
W
The Royal Veterinary College (RVC)
Waracle - Digital Health
Theradex (Europe) Ltd
We are Pioneer Group - Nottingham
Thermo Fisher Scientific
Wellcome Genome Campus
tranScrip
Wellcome Sanger Institute
Transine Therapeutics
Withers & Rogers LLP
Trident BioPharm Solutions Limited
Wren HealthCare Limited
Trio Medicines Ltd
Wren Therapeutics Limited
TTP plc
WuXi AppTec UK Ltd
Tuspark Cambridge
X
Xampla Limited
54 | One Nucleus Annual Review & Directory 2022/2023
Find Out More • Membership
• Purchasing Scheme
• Training Courses
• Member to Member Discounts
• One Nucleus Events
• Sector Data
• Industry Events
• Member Job Vacancies
• Facilities Management
• Member News
• Sponsorship Opportunities
• One Nucleus Blog
Did you know? If your employer is a One Nucleus Member, that means YOU’RE a Member too! How can the One Nucleus Membership benefit you? As a Member you can... • • • • •
Attend events for free or at a discounted rate Save money on third party events and services Post company news, jobs and events on our website Develop yourself via Training courses Write a guest blog for publication
Email info@onenucleus.com for more information.
www.onenucleus.com | 55
One Nucleus Limited 1012 Riverside, Babraham Research Campus, Cambridge CB22 3AT United Kingdom +44 (0) 1223 896 450 onenucleus.com
One Nucleus Limited Registered Office: 1012 Riverside, Babraham Research Campus, Cambridge CB22 3AT Registered in England & Wales No. 3990977
